4.5 Article

Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis

期刊

BREAST CANCER RESEARCH AND TREATMENT
卷 150, 期 2, 页码 439-445

出版社

SPRINGER
DOI: 10.1007/s10549-015-3315-5

关键词

Subsequent endometrial cancer; Increased risk; First primary breast cancer; ER/PR status

类别

资金

  1. NCI NIH HHS [P30 CA006973] Funding Source: Medline

向作者/读者索取更多资源

Estrogen receptor (ER)-positive breast cancer patients treated with tamoxifen are known to have an elevated risk of subsequent endometrial cancer. However, it is unclear if ER-negative patients also have a higher risk of endometrial cancer. This population-based study aims to evaluate whether breast cancer patients with distinctive ER and PR status possess differential risks in developing delayed endometrial malignancy. Data were obtained from the Surveillance, Epidemiology, and End Results program (1992-2009). Standardized incidence ratio (SIR) was calculated as the observed cases of endometrial cancers among breast cancer survivors compared with the expected cases in the general population. Data were stratified by latency periods, race, age, and calendar year of breast cancer diagnosis. We identified 2044 patients who developed a second primary endometrial cancer among 289,933 breast cancer survivors. The overall SIRs for subsequent endometrial cancers were increased in all of the four subtypes (ER+PR+, ER+PR-, ER-PR+, and ER-PR-) of breast cancer. SIR was increased for all latency periods except for the initial 6-11 months after breast cancer diagnosis. Stratifying by age of diagnosis, elevated SIRs in all ER/PR groups were statistically significant among patients diagnosed with breast cancer after the age of 40. Demographically, non-Hispanic whites had increased SIRs in all subtypes of breast cancer, while Hispanic whites had no statistically elevated SIRs. Here we showed that patients with invasive breast cancer have a higher risk of developing subsequent endometrial cancer regardless of ER or PR status. The increased risk among hormone receptor-negative breast cancer survivors raises concerns whether common etiological factors among these breast cancer subtypes increase the susceptibility to develop endometrial cancer. Lower threshold for routine endometrial cancer surveillance may be warranted.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer

Yun Ling, Gehao Liang, Qun Lin, Xiaolin Fang, Qing Luo, Yinghuan Cen, Maryam Mehrpour, Ahmed Hamai, Zihao Liu, Yu Shi, Juanmei Li, Wanyi Lin, Shijie Jia, Wenqian Yang, Qiang Liu, Erwei Song, Jun Li, Chang Gong

Summary: The study identified a circRNA circCDYL2 that is overexpressed in HER2(+) breast cancer patients resistant to trastuzumab, playing a critical role in maintaining HER2 signaling and contributing to trastuzumab resistance. High levels of circCDYL2 were associated with rapid recurrence and shorter survival in HER2(+) breast cancer patients, suggesting circCDYL2 as a potential biomarker for trastuzumab resistance.

MOLECULAR CANCER (2022)

Editorial Material Biology

Cancer challenges worldwide and in China: preparing for the inevitable

Jing Zhou, Wang Yang, Qiang Liu

SCIENCE CHINA-LIFE SCIENCES (2022)

Article Oncology

Association between weight change and breast cancer prognosis

Yi-Xin Zhang, Zhuo-Zhi Liang, Yun-Qian Li, Ying Lin, Qiang Liu, Xiao-Ming Xie, Lu-Ying Tang, Ze-Fang Ren

Summary: The association between weight change after breast cancer diagnosis and prognosis is inconsistent. Menopausal status and endocrine therapy have modifying effects on this association. Weight loss increases the risk of breast cancer progression, especially in post-menopausal women, while weight gain may reduce the risk of disease progression among patients with endocrine therapy.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Article Biology

Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors

Zijie Cai, Jingru Wang, Yudong Li, Qianfeng Shi, Liang Jin, Shunying Li, Mengdi Zhu, Qi Wang, Lok Lam Wong, Wang Yang, Hongna Lai, Chang Gong, Yandan Yao, Yujie Liu, Jun Zhang, Herui Yao, Qiang Liu

Summary: CDK4/6 inhibitors are standard treatment for advanced HR+/HER2- breast cancer, but resistance is inevitable. This study found that overexpression of Cyclin D1 and CDK4 proteins leads to resistance, and targeting the PI3K/mTOR pathway can restore sensitivity.

SCIENCE CHINA-LIFE SCIENCES (2023)

Article Multidisciplinary Sciences

Long noncoding RNA DIO3OS induces glycolytic-dominant metabolic reprogramming to promote aromatase inhibitor resistance in breast cancer

Xueman Chen, Rong Luo, Yunmei Zhang, Shuying Ye, Xin Zeng, Jiang Liu, Di Huang, Yujie Liu, Qiang Liu, Man-Li Luo, Erwei Song

Summary: This study identifies a long noncoding RNA DIO3OS as a driver of AI-resistance in breast cancer through the enhancement of aerobic glycolysis, highlighting its potential as a therapeutic target to reverse AI resistance in estrogen receptor positive breast cancer.

NATURE COMMUNICATIONS (2022)

Article Oncology

Survival in Breast Cancer Patients with Bone Metastasis: A Multicenter Real-World Study on the Prognostic Impact of Intensive Postoperative Bone Scan after Initial Diagnosis of Breast Cancer (CSBrS-023)

Liu Yang, Wei Du, Taobo Hu, Miao Liu, Li Cai, Qiang Liu, Zhigang Yu, Guangyu Liu, Shu Wang

Summary: This multicenter real-world study showed that intensive postoperative bone scan screening improved survival for breast cancer patients with bone metastasis, especially for those at clinical high-risk.

CANCERS (2022)

Article Engineering, Biomedical

Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy

Yi You, Yu Tian, Zhaogang Yang, Junfeng Shi, Kwang Joo Kwak, Yuhao Tong, Andreanne Poppy Estania, Jianhong Cao, Wei-Hsiang Hsu, Yutong Liu, Chi-Ling Chiang, Benjamin R. Schrank, Kristin Huntoon, DaeYong Lee, Ziwei Li, Yarong Zhao, Huan Zhang, Thomas D. Gallup, JongHoon Ha, Shiyan Dong, Xuefeng Li, Yifan Wang, Wen-Jing Lu, Eman Bahrani, Ly James Lee, Lesheng Teng, Wen Jiang, Feng Lan, Betty Y. S. Kim, Andrew S. Lee

Summary: The study found that extracellular vesicles (EVs) produced through cellular nanoporation can safely and effectively translate genetic material into functional proteins. In mice with photoaged skin, EVs carrying mRNA encoding for collagen induced collagen-protein grafts and reduced wrinkle formation. Intradermal delivery of mRNA-loaded EVs through a microneedle array resulted in prolonged and more uniform synthesis and replacement of collagen in the dermis. Intradermal delivery of EV-based COL1A1 mRNA may be an effective protein-replacement therapy for treating photoaged skin.

NATURE BIOMEDICAL ENGINEERING (2023)

Article Medicine, Research & Experimental

Metformin reverses oxidative stress-induced mitochondrial dysfunction in pre-osteoblasts via the EGFR/GSK-3β/calcium pathway

Fangming Cao, Keda Yang, Shui Qiu, Jie Li, Wen Jiang, Lin Tao, Yue Zhu

Summary: Oxidative stress is a major cause of osteoblast apoptosis in post-menopausal osteoporosis. Previous studies have shown that metformin can reverse the loss of bone mass in this condition. This study aimed to further investigate the effects and mechanisms of metformin under conditions of oxidative stress in post-menopausal osteoporosis.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2023)

Review Oncology

mRNA vaccination in breast cancer: current progress and future direction

Xiao-ting Jiang, Qiang Liu

Summary: Messenger RNA (mRNA) vaccination is highly successful against COVID-19 and has sparked tremendous interest. It is also viewed as a promising treatment strategy for cancer immunotherapy. However, breast cancer patients have limited access to immunotherapy benefits. This review discusses the potential of mRNA vaccination to convert cold breast cancer into hot and improve efficacy by combining appropriate vaccination platforms or other immunotherapies.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Multidisciplinary Sciences

LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein

Zijie Cai, Qianfeng Shi, Yudong Li, Liang Jin, Shunying Li, Lok Lam Wong, Jingru Wang, Xiaoting Jiang, Mengdi Zhu, Jinna Lin, Qi Wang, Wang Yang, Yujie Liu, Jun Zhang, Chang Gong, Herui Yao, Yandan Yao, Qiang Liu

Summary: This study reveals that a long non-coding RNA (EILA) that interacts with cyclin E1 is up-regulated in CDK4/6 inhibitor-resistant breast cancer cells and contributes to resistance by stabilizing cyclin E1 protein. EILA overexpression is associated with accelerated cell cycle progression and poor prognosis in breast cancer. Silencing EILA reduces cyclin E1 protein and restores sensitivity to CDK4/6 inhibitors both in vitro and in vivo.

SCIENCE ADVANCES (2023)

Article Biology

SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition

Jing Zhou, Mengdi Zhu, Qi Wang, Yiyuan Deng, Nianqiu Liu, Yujie Liu, Qiang Liu

Summary: Endocrine resistance is a major challenge in breast cancer therapy. Through screening five datasets, we identified 7 commonly dysregulated genes in endocrine-resistant breast cancer cells. Our study suggests that downregulation of SERPINA3, a direct target gene of estrogen receptor alpha, contributes to aromatase inhibitor resistance. ANKRD11 acts as a downstream effector of SERPINA3 in mediating endocrine resistance by interacting with HDAC3 and upregulating its activity.

COMMUNICATIONS BIOLOGY (2023)

Review Oncology

Targeting phagocytosis to enhance antitumor immunity

Kristin Huntoon, DaeYong Lee, Shiyan Dong, Abin Antony, Betty Y. S. Kim, Wen Jiang

Summary: Many patients with advanced or hard-to-treat cancer have seen improved outcomes with immunotherapy that targets adaptive immune checkpoints. However, innate immune checkpoints also play a crucial role in immune evasion by cancer cells and may be potential targets for cancer immunotherapy. This review discusses the disruption of phagocytic clearance by cancer cells and the potential impact of blocking phagocytosis checkpoints on activating anti-tumor immune responses. The authors propose a more effective combination immunotherapy strategy by targeting tumor-intrinsic processes that inhibit innate immune surveillance, such as phagocytosis, and incorporating both innate and adaptive immune responses.

TRENDS IN CANCER (2023)

Article Medicine, Research & Experimental

Waking immune-resistant tumors with neddylation

Kristin Huntoon, Wen Jiang, Betty Y. S. Kim

Summary: The CD47/SIRP alpha axis plays a crucial role in cancer immune evasion, and targeting it can sensitize previously resistant colorectal cancer cells to immunotherapies. The study by Li et al. reveals that neddylation of SHP2 inhibits its activity and cotargeting SHP2 and immune checkpoints may be effective in immunotherapy-resistant tumors.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

MRI-based radiomic models to predict surgical margin status and infer tumor immune microenvironment in breast cancer patients with breast-conserving surgery: a multicenter validation study

Jiafan Ma, Kai Chen, Shunrong Li, Liling Zhu, Yunfang Yu, Jingwu Li, Jie Ma, Jie Ouyang, Zhuo Wu, Yujie Tan, Zifan He, Haiqing Liu, Zhilong Pan, Haojiang Li, Qiang Liu, Erwei Song

Summary: An MRI-based radiomic model was developed to predict the risk of margin positivity in breast-conserving surgery. The model can stratify patients into different risk subgroups and is associated with tumor immune-microenvironment alterations.

EUROPEAN RADIOLOGY (2023)

暂无数据